Skip to main content
Medical Reference · Condition Monograph

Cholangiocarcinoma

담도암

Cholangiocarcinoma (bile duct cancer) is a cancer that arises in the bile ducts, the passages through which bile produced in the liver flows.

History

Cholangiocarcinoma (bile duct cancer) is a cancer that arises in the bile ducts, the passages through which bile produced in the liver flows. In the past, it was often recorded loosely as "liver cancer" or "cancer around the pancreas," or classified together with gallbladder cancer. This was because the bile ducts lie deep inside the body, making small lesions difficult to see, and by the time symptoms appeared, the bile duct was often already blocked or the cancer had already invaded surrounding organs. Over time, as surgically removed tissue was analyzed in detail and imaging tests advanced, it became clear that cholangiocarcinoma behaves differently depending on its location.

Today, it is usually described by its "site of origin": intrahepatic cholangiocarcinoma, which begins in the small bile ducts inside the liver; perihilar (hilar) cholangiocarcinoma, which arises at the hepatic hilum; and distal cholangiocarcinoma, which occurs lower down toward the duodenum. This distinction is not simply a matter of naming; it determines when symptoms appear, how extensive surgery must be, and even what the pattern of recurrence looks like. As abdominal ultrasound became widely available, it became relatively easy to check whether the bile ducts are dilated, and CT, MRI, and magnetic resonance cholangiopancreatography (MRCP) have greatly changed the diagnostic process.

In terms of treatment, endoscopic retrograde cholangiopancreatography (ERCP) made it possible to drain blocked bile with a stent, allowing jaundice and infection to be controlled. Surgical techniques have also become standardized for major operations such as liver resection, bile duct reconstruction, and pancreaticoduodenectomy, creating the "possibility of cure." More recently, with the development of precision medicine, which analyzes genetic changes in the tumor to find targets, there is growing evidence for choosing new drugs in addition to conventional chemotherapy in some patients.

Causes

Cholangiocarcinoma is difficult to explain by a single cause. However, there is a common thread pointed out by many studies: "an environment in which the bile ducts undergo repeated inflammation and injury over a long period." When bile does not flow well, when the bile ducts are repeatedly infected, or when they are structurally narrowed so that irritation persists, the bile duct cells keep repeating regeneration and repair. The longer this process continues, the greater the chance that errors accumulate in the cells' genes.

A representative risk factor is primary sclerosing cholangitis (PSC). PSC is a disease in which the bile ducts become narrowed and scarred due to chronic inflammation, and it is known to greatly increase the risk of cholangiocarcinoma. Because PSC can occur together with inflammatory bowel disease, especially ulcerative colitis, people with such a history should have regular follow-up in specialist care. Conditions in which the structure of the bile ducts itself is abnormal, such as choledochal cysts and Caroli disease, also increase the risk.

In East Asia, infection with liver flukes (parasites associated with eating raw freshwater fish) has been reported to be associated with cholangiocarcinoma by leaving long-lasting inflammation in the bile ducts. Chronic liver diseases such as obesity, diabetes, fatty liver, liver cirrhosis, and hepatitis B and C may also be associated with the risk. In practice, it is very important to be evaluated quickly when warning signs such as jaundice, itching (pruritus), or unexplained weight loss appear.

Genetic Epidemiology

In cholangiocarcinoma, it is uncommon for "inheritance passed down in the family" to be the direct cause. Instead, what has become more important in recent medicine is what genetic changes have occurred only within the cancer cells (that is, the molecular characteristics of the tumor). Even within the same cholangiocarcinoma, the cancer cells' "broken switches" can differ from patient to patient, and that difference can determine the treatment options. In intrahepatic cholangiocarcinoma in particular, changes such as IDH1 mutations and FGFR2 fusions may be found in some patients, and in such cases targeted therapy aimed at those changes is considered.

In addition, factors such as BRAF mutations, HER2 amplification, NTRK fusions, and high microsatellite instability (MSI-H) are observed in some patients. These markers are not very frequent, but they become "information that can change the direction of treatment for those to whom they apply." Tests such as next-generation sequencing (NGS) are used to identify this information. From a layperson's point of view, it can be thought of as going one step beyond receiving a diagnosis of "cholangiocarcinoma" through biopsy, to identifying what "genetic fingerprint" that cholangiocarcinoma has.

Regarding family history, there are reports that hereditary cancer syndromes that raise the risk of multiple cancers, such as Lynch syndrome, can increase the risk of biliary tract cancer. Ultimately, the "genetic epidemiology" of cholangiocarcinoma is developing in a direction that places more weight on what genetic changes are found in an individual patient's tumor than on the genetic predisposition of the population.

General Epidemiology

Cholangiocarcinoma is relatively rare among all cancers, but its incidence varies greatly by region and population. In general, the risk increases with age, so it is more common from middle age onward, and it is often reported slightly more frequently in men. An important factor creating regional differences is the distribution of risk factors. In Western countries, PSC is mentioned as a relatively representative risk factor, while in some parts of East Asia, factors such as liver fluke infection, intrahepatic stones, and chronic cholangitis are observed more often. In regions with a high prevalence of chronic liver disease such as hepatitis B and C and liver cirrhosis, intrahepatic cholangiocarcinoma may be observed relatively more often.

The biggest epidemiological problem with cholangiocarcinoma is that "early detection is difficult." Because the bile ducts lie deep in the body, there are almost no symptoms even when a small lesion is present, and by the time symptoms appear, bile flow is often already blocked or surrounding tissue has already been invaded. Recently, with better access to imaging tests and advances in treatment, a trend toward improved survival has been reported in some patient groups. Overall, however, the stage at diagnosis strongly determines the prognosis, and the importance of managing risk factors and following high-risk groups continues to be emphasized.

Pathogenesis

The process by which cholangiocarcinoma develops can be explained as "bile duct cells losing normal growth control as they repeatedly undergo injury and recovery over a long period." When bile stagnates or infections recur, inflammation develops in the inner lining of the bile duct, and cell division becomes frequent during the healing process. The more cells divide, the greater the chance that genetic errors accumulate, and some of these cause changes that make cells grow out of control. Inflammation can increase substances that damage cells through mechanisms such as oxidative stress.

In cholangiocarcinoma, the tumor's position relative to surrounding organs is very important for prognosis. At the hepatic hilum, the bile ducts run close to large blood vessels such as the portal vein and hepatic artery, and they also abut the head of the pancreas. Therefore, as the cancer grows, it not only blocks the bile duct and causes jaundice but can also encase or invade blood vessels, making surgery difficult. Lymph node metastasis is also relatively common, and the cancer can spread within the liver or to the peritoneum, so staging is important.

It has recently become known that the tumor microenvironment, that is, the immune cells, fibrous tissue, and vascular structures surrounding the cancer, affects cancer growth and drug response. For this reason, immunotherapy is considered in some patients, and treatment strategies are developing in a more refined direction together with the molecular characteristics of the tumor.

Symptoms

The symptoms of cholangiocarcinoma vary depending on the location of the tumor and how much bile flow is blocked. The most representative symptom is jaundice. The skin and the whites of the eyes (sclera) turn yellow, the urine becomes dark, and the stool may become pale, gray or white in color. This is because bile cannot pass into the intestine and backs up into the blood. Jaundice is especially pronounced when the extrahepatic bile duct is blocked, and it is an important reason people seek medical care. Itching (pruritus) is also common. When bile components accumulate in the blood, the skin can become severely itchy, and it is often worse at night, disturbing sleep.

Symptoms such as right upper abdominal pain, abdominal discomfort, indigestion, and nausea may also occur. Weight loss, loss of appetite, and fatigue are common systemic symptoms in advanced cancer. If fever and chills accompany these symptoms, cholangitis, a bacterial infection occurring while the bile duct is blocked, should be suspected, and this may require emergency bile drainage and antibiotic treatment.

In intrahepatic cholangiocarcinoma, the bile duct is not significantly blocked in the early stages, so jaundice sometimes appears late. Therefore, it is sometimes discovered incidentally on imaging tests performed during a health checkup or for other reasons, without any particular symptoms. Conversely, extrahepatic cholangiocarcinoma blocks bile flow relatively early, so jaundice may appear first, and the pattern of symptoms may feel different.

Signs

Signs are objective findings that medical staff confirm through physical examination or tests. Signs commonly seen in cholangiocarcinoma are scleral icterus and skin jaundice, and scratch marks caused by itching. Blood tests may show a "cholestatic" pattern in which levels such as alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) rise along with bilirubin. On abdominal examination, there may be right upper quadrant tenderness, or rarely a palpable mass. When the extrahepatic bile duct is blocked, the gallbladder may become distended and palpable, which can be an important clue depending on the situation.

When cholangitis is present, fever, chills, and generalized weakness appear and inflammatory markers rise. In this case, liver function can deteriorate rapidly, so prompt evaluation is needed. The tumor markers CA 19-9 and carcinoembryonic antigen (CEA) can be elevated in cholangiocarcinoma, but they can also rise with bile duct obstruction or inflammation alone, so they should be interpreted "for reference only." On imaging tests, findings such as bile duct dilation, stricture, mass, vascular invasion, lymph node enlargement, liver metastasis, and peritoneal metastasis are considered together to determine the stage and direction of treatment.

Screening

Screening tests are tests to detect disease early in people without symptoms. Because cholangiocarcinoma has a low incidence in the general population and it is difficult to reliably detect early lesions with a single simple test, there is no standard screening test recommended for everyone. Instead, early detection is attempted in high-risk groups in the form of "surveillance." The representative high-risk group is patients with PSC. In this case, the attending physician may evaluate the patient at regular intervals using a combination of liver function tests, tumor markers, and imaging tests.

As for testing tools, abdominal ultrasound is relatively simple and involves no radiation exposure, so it is widely used as a first-line evaluation, but it can miss small lesions. MRCP can show the shape of the bile ducts in detail noninvasively, so it is sometimes used in the surveillance of high-risk groups. CT is useful for staging, but because it involves radiation exposure, it is difficult to repeat indiscriminately for screening purposes.

There is still no established method for screening for cholangiocarcinoma early with blood tests alone. CA 19-9 may be helpful in some cases, but it has a considerable number of false positives, so it has limitations as a stand-alone screening test. The realistic strategy is to "accurately identify high-risk groups, evaluate without delay when symptoms change, and follow up regularly with a focus on imaging."

Diagnosis

Diagnosis of cholangiocarcinoma has three goals. First, to confirm whether the bile duct is blocked and where the blockage is. Second, to determine the extent of the tumor and whether it has metastasized in order to establish the stage. Third, when possible, to obtain tissue to confirm the diagnosis and to link it to molecular testing in order to broaden treatment options. In the initial evaluation, blood tests are used to check for a cholestatic pattern and inflammation. After abdominal ultrasound (US) is used to check for bile duct dilation, CT is used to evaluate the extent of the tumor, liver involvement, vascular invasion, and lymph node and distant metastases. MRI and MRCP show the shape of the bile duct stricture, the length of the lesion, and the structure of the bile ducts inside the liver in more detail, making them important for surgical planning.

ERCP is a test that directly visualizes the bile ducts with contrast and can also be used for treatment at the same time. With ERCP, the narrowed area can be identified and tissue can be obtained by brush cytology or biopsy, and at the same time a stent can be inserted to drain bile. If ERCP is difficult because of the location of the lesion or for anatomical reasons, jaundice may be controlled by inserting a drainage tube through the skin, as in percutaneous transhepatic biliary drainage (PTBD). For lesions in the distal bile duct or adjacent to the pancreas, endoscopic ultrasound (EUS) can be used to view the lesion up close, and tissue can be obtained by fine-needle aspiration (FNA) or biopsy.

Once sufficient tissue is obtained, molecular testing such as NGS can be considered to check the possibility of targeted therapy. When necessary, positron emission tomography (PET) is also used as an aid to staging. The diagnosis is completed by combining imaging, blood tests, tissue pathology, and molecular testing step by step.

Treatment

The most important branching point in the treatment of cholangiocarcinoma is "whether surgery aimed at cure is possible." If surgery is possible, the aim is complete resection by removing the bile duct containing the tumor together with the surrounding liver tissue and lymph nodes. The surgical approach differs depending on the location. For intrahepatic cholangiocarcinoma, liver resection is central; for perihilar cholangiocarcinoma, bile duct resection and liver resection are performed together, and the bile duct often needs to be reconstructed. Distal cholangiocarcinoma may require a major operation that removes the head of the pancreas and part of the duodenum together. After surgery, adjuvant chemotherapy may be considered to reduce the risk of recurrence.

When surgery is difficult from the outset or metastasis is present, systemic chemotherapy becomes the center of treatment. Standard chemotherapy uses a combination of several drugs, and the plan varies depending on the patient's general condition, liver function, and whether jaundice has been controlled. Recently, when features such as FGFR2 fusions or IDH1 mutations are identified, drugs aimed at those targets may be considered. In addition, immunotherapy such as immune checkpoint inhibitors (ICI) may be considered in some patients, and the possibility depends on the immunological characteristics of the tumor (such as MSI-H).

Palliative care is also an important pillar of treatment. If the bile duct is blocked and jaundice and itching are severe, bile is drained by inserting a stent through ERCP or placing a drainage tube through PTBD. If cholangitis develops, antibiotics and drainage are needed on an emergency basis. Pain control, nutritional management, relief of itching, and psychological support should be provided together regardless of the stage of treatment, and they greatly affect quality of life.

Prognosis

The prognosis of cholangiocarcinoma varies greatly depending on the location and stage of the tumor and, above all, on "whether it could be completely removed by surgery." In general, the more the tumor remains localized, without lymph node metastasis, and the more clean surgical margins are achieved, the higher the chance of long-term survival. On the other hand, if there is extensive vascular invasion or distant metastasis at the time of diagnosis, surgery aimed at cure is difficult, and the goal of treatment shifts toward slowing the progression of the disease and reducing symptoms. The hepatic hilum in particular is close to large blood vessels, so even a small spread of the tumor can make surgery difficult.

Practical factors that improve prognosis are prompt diagnosis and appropriate specialized treatment. When symptoms such as jaundice, fever, or weight loss develop, being evaluated without delay and being treated at an institution capable of multidisciplinary care covering surgery, endoscopy, and chemotherapy allows a more refined treatment strategy to be established. If tissue can be obtained, checking the possibility of targeted therapy through molecular testing can be of meaningful help to some patients. Because complications during treatment, such as cholangitis and worsening liver function, can greatly affect prognosis and quality of life, you should consult your medical team immediately if warning symptoms occur.

Prevention

There is still no definite way to "completely" prevent cholangiocarcinoma. However, reducing risk factors and managing high-risk groups well can lower the risk or at least increase the chance of early detection. The key concept of prevention is "reducing chronic bile duct inflammation and bile stasis." If you have a high-risk condition such as PSC, choledochal cyst, Caroli disease, recurrent cholangitis, or intrahepatic stones, it is important to receive regular follow-up in gastroenterology or hepatobiliary-pancreatic specialist care. For choledochal cysts, preventive surgery is sometimes considered depending on the case. In regions where liver fluke infection is a problem, it helps to avoid eating raw freshwater fish and, if infection is confirmed, to treat it appropriately to reduce chronic inflammation.

Protecting overall liver health is also indirectly important for lowering the risk of intrahepatic cholangiocarcinoma. If you have hepatitis, it is advisable to receive treatment, drink alcohol in moderation, and manage your weight and control diabetes so that the condition does not progress to fatty liver and liver cirrhosis.

When symptoms such as jaundice, itching, a change in urine color, or unexplained weight loss occur, the most realistic primary prevention is to seek medical care promptly rather than dismissing them as "just age." Because cholangiocarcinoma is a field in which treatment is advancing rapidly, if you have been diagnosed or are in a high-risk state, establishing a clear follow-up plan with your medical team helps prognosis and quality of life.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.